Navigation Links
DePuy & Transvaginal Mesh Lawsuit Settlement Funding Leads Legal-Bay to Banner 2nd Quarter
Date:7/10/2012

NEW YORK, July 10, 2012 /PRNewswire/ -- Legal-Bay LLC, the lawsuit settlement funding company, announced today that the company had a robust 2nd quarter mostly due to high volume in assisting victims with pre-settlement funding of the DePuy and Johnson & Johnson Hip Implant Recall, as well as Transvaginal Mesh products.  Additionally, the company expanded its operations to a new "state of the art" facility with increased staff, additional funding capital, and newly aligned marketing partners. 

The sales of both DePuy and the various mesh cases (vaginal, pelvic, bladder slings, and hernia Kugel mesh) were due to both of the litigations slowing down without any settlement news.  However, Legal-Bay believes that the average settlement value for both DePuy and transvaginal mesh cases could be from $500K to $1mm depending on damages and other factors.  Legal-Bay provides individuals with what plaintiff's refer to as "lawsuit loans" with up to $50K on each of these cases.  However, the lawsuit cash advance is not a lawsuit loan and only needs to be paid back if the case is actually won. 

Patty Kirby, Head of Client Relations, commented about the company's success, "Most of our DePuy lawsuit funding and Mesh clients cannot wait and need money today, so our program enables them to access $50K immediately off their case and still be left with approximately $450K at settlement on a case valued at $500K. The 2nd quarter our applications were up across the board, as we have recently launched a separate division for accident lawsuit funding cases.  We added staff to handle this influx of business.  We are now equipped to handle the largest funding cases with extremely low rates and the absolute fastest turnaround time's industry wide."

Legal-Bay says that they have also seen substantial growth in Commercial Litigation, Quit Tam or Whistleblower, Wrongful Imprisonment, FELA, Jones Act, Mesothelioma, and Actos Pharmaceutical case funding in 2012. 

Plaintiffs in need of a DePuy, Transvaginal Mesh lawsuit funding, car or commercial truck accident funding or any other lawsuit settlement funding can apply directly to lawsuitssettlementfunding.com or call toll free at 877.571.0405 where agents are standing by 24 hours a day to assist you. 

Contact:  Patty Kirby, Head of Client Relations info@legal-bay.com, ph. 877.571.0405


'/>"/>
SOURCE Legal-Bay LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
3. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
4. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
8. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
9. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
10. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology ... have severe consequences to overall dental health, including complications with speech, eating, and overcompensation ... dental implants to replace lost teeth. As the number of tooth replacements increase, it ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Hackensack, N.J. has been honored by Enterprising Women magazine as one of its ... world’s top women business owners. Winners have demonstrated that they have fast-growth businesses, ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
Breaking Medicine News(10 mins):